糖尿病合并高A1C人群中综合财务毒性评分(COST)的测量与验证
本研究在600名糖尿病合并高A1C成人中检验11条目COST-FACIT量表的信度与结构效度,发现其呈两因子结构(一般财务状况7条目α=0.86;疾病对财务状况影响4条目α=0.73),天花板效应2%、地板效应7%;更差财务毒性与高A1C、糖尿病痛苦、更多慢性病及抑郁症状相关(P<0.01)。结论支持该工具在糖尿病高A1C成人中的信效度,但需更多研究支持其作为临床相关患者中心工具用于糖尿病照护。
要点
- COST-FACIT在糖尿病高A1C成人中显示两因子结构,内部一致性信度良好(α=0.86与0.73)。
- 量表存在天花板效应2%、地板效应7%。
- 更差财务毒性与女性、贫困线以下、政府医保、中年、非劳动力、低教育程度及成本应对行为相关(P<0.01)。
核心结论
- 研究结果支持COST-FACIT工具在糖尿病合并高A1C成人中的信度和效度。
- 需要更多研究支持COST-FACIT作为临床相关患者中心工具用于糖尿病照护。
研究设计与样本
- 在600名糖尿病合并高A1C成人样本中检验11条目COST-FACIT的信度和结构效度。
- 分析包括探索性因子分析、Cronbach α内部一致性信度、地板/天花板效应、已知组效度和预测效度。
主要发现
- COST-FACIT呈现两因子结构:一般财务状况(7条目,α=0.86)和疾病对财务状况的影响(4条目,α=0.73)。
- 量表在2%的参与者中显示天花板效应,在7%中显示地板效应。
- 更差财务毒性评分见于女性、贫困线以下、政府资助医保、中年、非劳动力及教育程度较低的成人(P<0.01)。
- 采取成本应对行为(如减少或跳过药物、延迟照护、借钱、刷爆信用卡额度、不付账单)者财务毒性更差(P<0.01)。
- 在全量表及两因子的回归模型中,更差财务毒性与更高A1C(P<0.01)、更高糖尿病痛苦水平(P<0.01)、更多慢性病(P<0.01)及更多抑郁症状(P<0.01)相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需要更多研究支持COST-FACIT作为临床相关患者中心工具用于糖尿病照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) is a validated instrument measuring financial distress among people with cancer. The reliability and construct validity of the 11-item COST-FACIT were examined in adults with diabetes and high A1C. RESEARCH DESIGN AND METHODS: We examined the factor structure (exploratory factor analysis), internal consistency reliability (Cronbach α), floor/ceiling effects, known-groups validity, and predictive validity among a sample of 600 adults with diabetes and high A1C. RESULTS: COST-FACIT demonstrated a two-factor structure with high internal consistency: general financial situation (7-items, α = 0.86) and impact of illness on financial situation (4-items, α = 0.73). The measure demonstrated a ceiling effect for 2% of participants and floor effects for 7%. Worse financial toxicity scores were observed among adults who were women, were below the poverty line, had government-sponsored health insurance, were middle-aged, were not in the workforce, and had less educational attainment (P < 0.01). Worse financial toxicity was observed for those engaging in cost coping behaviors, such as taking less or skipping medicines, delaying care, borrowing money, "maxing out" the limit on credit cards, and not paying bills (P < 0.01). In regression models for the full measure and its two factors, worse financial toxicity was correlated with higher A1C (P < 0.01), higher levels of diabetes distress (P < 0.01), more chronic conditions (P < 0.01), and more depressive symptoms (P < 0.01). CONCLUSIONS: Findings support both the reliability and validity of the COST-FACIT tool among adults with diabetes and high A1C levels. More research is needed to support the use of the COST-FACIT tool as a clinically relevant patient-centered instrument for diabetes care.
引用
- Patel MR, Zhang G, Heisler M, et al. Measurement and Validation of the Comprehensive Score for Financial Toxicity (COST) in a Population With Diabetes. Diabetes Care. 2022. PMID: 36048837. doi:10.2337/dc22-0494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。